virus
among
common
caus
opportunist
infect
transplant
risk
viral
infect
function
specif
viru
encount
intens
immun
suppress
use
prevent
graft
reject
host
factor
govern
suscept
although
cytomegaloviru
common
opportunist
pathogen
seen
transplant
recipi
numer
virus
also
affect
outcom
case
prevent
measur
pretranspl
screen
prophylact
antivir
therapi
posttranspl
viral
monitor
may
limit
impact
infect
recent
advanc
laboratori
monitor
antivir
therapi
improv
outcom
studi
viral
latenc
reactiv
cellular
effect
viral
infect
provid
clue
futur
strategi
prevent
treatment
viral
infect
paper
summar
major
viral
infect
seen
follow
transplant
discuss
strategi
prevent
manag
potenti
pathogen
solid
organ
transplant
therapeut
option
mani
human
diseas
liver
kidney
heart
lung
transplant
becom
standard
therapi
select
endstag
diseas
howev
complic
infect
allograft
reject
relat
immunosuppress
therapi
remain
major
caus
morbid
mortal
follow
solid
organ
transplant
epidemiolog
viral
infect
result
commun
exposur
influenza
adenoviru
wherea
commonli
transmit
allograft
cytomegaloviru
epsteinbarr
viru
other
result
distant
exposur
reactiv
set
immun
suppress
chicken
pox
varicella
zoster
shingl
multipl
simultan
infect
viral
nonvir
also
common
cytomegaloviru
cmv
human
herp
viru
cytomegaloviru
pneumocysti
effect
viral
infect
classifi
direct
indirect
fever
neutropenia
syndrom
invas
diseas
pneumonia
enter
mening
enceph
consid
direct
effect
indirect
effect
due
releas
cytokin
chemokin
growth
factor
respons
viral
infect
bodi
deepen
immunosuppress
increas
risk
opportunist
infect
addit
viral
infect
may
alter
express
surfac
antigen
eg
histocompat
antigen
provok
graft
reject
andor
caus
dysregul
cellular
prolifer
contribut
oncogenesi
multipl
observ
studi
implic
infect
hhv
andor
hhv
risk
factor
cmv
diseas
cmv
infect
may
trigger
hhv
hhv
reactiv
recent
coinfect
polyoma
viru
cmv
report
kidney
transplant
recipi
polyoma
viru
may
induc
cmv
gene
express
stimul
cellular
regul
protein
gene
regul
protein
increas
viral
replic
persist
may
contribut
allograft
injuri
fibrosi
chronic
reject
virusspecif
cell
crossreact
alloantigen
alter
memori
allospecif
cell
pool
may
modul
allograft
surviv
transplant
toler
viral
infect
also
lead
gener
crossreact
cell
direct
share
antigen
viru
graft
molecular
mimicri
neoantigen
gener
viral
express
within
allograft
environ
scientif
world
journal
mani
viral
infect
renal
transplant
result
reactiv
latent
viral
infect
host
graft
whether
viru
awak
depend
natur
viru
tissu
infect
host
immun
respons
latent
virus
metabol
inact
wherea
other
constantli
replic
low
level
determin
effect
host
immun
respons
multipl
factor
contribut
viral
activ
transplant
includ
immun
suppress
especi
reduct
cytotox
immun
graft
reject
therapi
inflamm
cytokin
tissu
injuri
host
respons
also
less
effect
mismatch
major
histocompat
antigen
organ
donor
host
reduc
efficaci
direct
pathway
antivir
cellular
immun
respons
factor
render
allograft
suscept
invas
viral
infect
optim
approach
infect
solid
organ
transplant
recipi
prevent
fail
prompt
aggress
diagnosi
therapi
essenti
sourc
infecti
agent
transplant
includ
endogen
organ
allograft
environ
import
principl
consid
evalu
solidorgan
transplant
recipi
immunocompromis
host
infect
usual
inflammatori
respons
infecti
organ
may
attenu
due
immunosuppress
therapi
therefor
sign
symptom
infect
may
blunt
diagnost
techniqu
may
compromis
pretranspl
screen
potenti
organ
donor
recipi
essenti
part
solid
organ
transplant
sever
guidelin
pretranspl
screen
publish
recent
includ
consensu
confer
immunocompromis
patient
american
societi
transplant
clinic
practic
guidelin
evalu
renal
transplant
candid
american
societi
transplant
physician
clinic
practic
guidelin
evalu
live
renal
transplant
donor
pretranspl
screen
donor
recipi
afford
opportun
assess
safeti
transplant
determin
prophylaxi
prevent
strategi
util
transplant
detect
fulli
treat
activ
infect
potenti
recipi
prior
transplant
updat
vaccin
statu
potenti
recipi
educ
patient
famili
prevent
measur
generos
altruism
organ
donat
nation
frontier
due
increas
migrat
intern
travel
also
led
rise
number
donor
foreign
countri
link
increas
risk
infect
specif
area
world
may
persist
latent
chronic
form
donor
may
transmit
transplant
futur
advanc
like
includ
increas
use
rapid
molecular
diagnost
test
base
genom
proteom
metabolom
highthroughput
measur
analysi
metabolit
possibl
addit
test
emerg
pathogen
paper
focuss
acut
recurr
viral
infect
occur
adult
renal
transplant
tabl
human
cytomegalovirushuman
herpesviru
cmv
belong
order
herpesviral
famili
herpesvirida
subfamili
betaherpesvirina
genu
cytomegaloviru
speci
human
herpesviru
symptomat
cmv
infect
occur
transplant
recipi
signific
caus
increas
morbid
mortal
popul
compar
organ
transplant
recipi
renal
transplant
patient
lower
risk
cmv
part
due
lower
burden
latent
viru
renal
allograft
incid
cmv
renal
transplant
popul
estim
percent
renal
transplant
popul
infect
occur
acut
reactiv
latent
viru
absenc
prophylaxi
acut
infect
like
occur
first
third
month
follow
transplant
immun
suppress
maximum
howev
onset
acut
infect
delay
use
prophylact
antivir
earli
posttranspl
period
current
cmv
typic
occur
cessat
antivir
prophylaxi
later
first
year
cmv
may
transmit
transplant
recipi
via
infect
donor
organ
cellular
blood
product
three
major
pattern
cmv
transmiss
observ
solid
organ
transplant
recipi
primari
infect
develop
cmvseroneg
individu
receiv
cell
latent
infect
viru
seroposit
donor
secondari
infect
reactiv
infect
develop
endogen
latent
viru
reactiv
cmvseroposit
individu
posttransplant
superinfect
reinfect
occur
seroposit
recipi
receiv
latent
infect
cell
seroposit
donor
viru
reactiv
posttransplant
donor
origin
seroneg
recipi
organ
seroposit
donor
highest
risk
without
prophylaxi
cmv
infect
hve
report
occur
recipi
wich
develop
cmv
diseas
studi
effect
cmv
diseas
asymptomat
infect
graft
function
risk
acut
reject
conflict
result
studi
shown
associ
cmv
diseas
cmv
infect
increas
graft
loss
other
fail
shown
effect
saged
et
al
show
cmv
diseas
surprisingli
even
asymptomat
cmv
infect
independ
risk
factor
overal
mortal
beyond
day
posttransplant
reduc
graft
surviv
patholog
level
cmv
replic
kidney
tissu
caus
acut
allograft
dysfunct
usual
improv
ganciclovir
treatment
reduct
immunosuppress
infect
cmv
also
implic
chronic
allograft
nephropathi
major
reason
loss
renal
allograft
first
year
transplant
cmv
diseas
link
chronic
reject
arteri
myointim
thicken
similar
atherosclerot
coronari
diseas
howev
still
unclear
whether
viru
lead
directli
glomerulonephropathi
scientif
world
journal
scientif
world
journal
present
cmv
may
variabl
rang
asymptomat
infect
defin
presenc
activ
viral
replic
end
organ
dissemin
involv
commonli
patient
present
symptom
fever
malais
sometim
associ
leukopenia
thrombocytopenia
gastroenter
pneumon
hepat
rare
retin
central
nervou
system
involv
type
immunosuppress
affect
present
sever
ill
serolog
screen
antibodi
cmv
perform
donor
recipi
transplant
identifi
patient
risk
transplant
infect
might
benefit
prevent
strategi
two
strategi
commonli
use
cmv
prevent
univers
prophylaxi
preemptiv
therapi
univers
prophylaxi
involv
give
antivir
therapi
atrisk
patient
begin
immedi
transplant
defin
time
period
preemptiv
therapi
patient
monitor
regular
interv
earli
evid
cmv
replic
prior
onset
clinic
symptom
use
laboratori
assay
patient
earli
replic
treat
antivir
therapi
prevent
symptomat
diseas
approach
advantag
disadvantag
must
consid
context
patient
allograft
preemptiv
therapi
may
decreas
drug
cost
toxic
howev
requir
excel
logist
coordin
order
obtain
receiv
act
result
time
fashion
difficult
patient
live
quit
distanc
transplant
center
prophylaxi
might
theoret
advantag
prevent
reactiv
virus
hhv
theoret
may
like
prevent
indirect
effect
cmv
cmv
resist
observ
strategi
drug
evalu
univers
prophylaxi
includ
acyclovir
ganciclovir
valacyclovir
valganciclovir
immun
globulin
prepar
base
current
data
optim
preemptiv
strategi
unknown
preemptiv
therapi
well
suit
transplant
recipi
low
intermedi
risk
cmv
diseas
prophylaxi
may
better
suit
high
risk
studi
conclud
preemptiv
valganciclovir
therapi
valacyclovir
prophylaxi
equal
effect
prevent
cmv
diseas
renal
transplant
differ
overal
cost
conclus
obtain
studi
use
ganciclovir
antivir
therapi
metaanalysi
trial
patient
perform
compar
outcom
variou
prophylact
antivir
transplant
patient
risk
cmv
diseas
demonstr
prophylaxi
decreas
cmv
diseas
cmv
infect
allcaus
mortal
metaanalysi
show
ganciclovir
effect
acyclovir
prevent
cmv
diseas
valganciclovir
intraven
ganciclovir
found
effect
oral
ganciclovir
prophylaxi
howev
use
ganciclovir
may
associ
greater
rate
cmv
resist
compar
valganciclovir
least
highest
risk
recipi
length
prophylact
treatment
vari
institut
gener
last
minimum
month
mani
techniqu
current
avail
aid
diagnosi
cmv
diseas
includ
serolog
viral
cultur
shell
vial
cultur
antigenemia
test
qualit
quantit
nucleic
acid
detect
assay
although
histopatholog
diagnosi
remain
gold
standard
noninvas
measur
viremia
use
commonli
determin
presenc
absenc
cmv
antigenemia
assay
detect
lower
matrix
phosphoprotein
leukocyt
nucleic
acid
test
includ
cmvpcr
hybridcaptur
dna
typic
use
choic
methodolog
vari
among
center
clinic
use
test
ideal
good
sensit
specif
abl
detect
asymptomat
cmv
infect
predict
cmv
diseas
thu
help
treatment
decis
technic
easi
perform
although
gener
accept
sensit
methodolog
cmv
detect
nucleic
acid
test
wellstandard
recent
studi
demonstr
substanti
interlaboratori
variabl
quantit
cmv
assay
two
promin
gap
neurolog
diseas
includ
chorioretin
gastrointestin
diseas
includ
invas
coliti
gastriti
syndrom
cmv
assay
often
neg
invas
biopsi
diagnos
often
necessari
schedul
screen
link
individu
risk
infect
patient
treat
cmv
infect
assay
provid
endpoint
neg
assay
therapi
reiniti
prophylaxi
patient
high
risk
complet
prophylaxi
weekli
biweekli
screen
consid
assur
absenc
infect
month
treatment
activ
cmv
diseas
requir
combin
immunomodul
antivir
therapi
reduct
immunosuppress
possibl
standard
care
treat
cmv
diseas
week
intraven
ganciclovir
mgkg
twice
daili
dose
adjust
renal
dysfunct
demonstr
clinic
virolog
respons
therapi
contrast
oral
ganciclovir
use
treatment
cmv
diseas
limit
absorpt
poor
bioavail
seroneg
patient
slow
respond
therapi
addit
cmv
hyperimmun
globulin
mgkg
per
dose
intraven
given
monthli
may
use
recent
introduct
valganciclovir
allow
oral
treatment
cmv
diseas
sot
recipi
trial
renal
transplant
recipi
symptomat
cmv
diseas
viremia
treat
valganciclovir
clear
infect
none
experienc
relaps
mean
followup
month
recent
multicent
random
control
trial
perform
solid
organ
transplant
recipi
demonstr
oral
valganciclovir
inferior
intraven
ganciclovir
initi
treatment
cmv
viremia
inde
valganciclovir
recent
shown
effect
intraven
ganciclovir
treatment
mildtomoder
ie
nonsever
cmv
diseas
durat
treatment
cmv
diseas
individu
guid
virolog
clinic
surveil
undetect
viraemia
achiev
prior
scientif
world
journal
discontinu
therapi
order
reduc
risk
clinic
relaps
previou
studi
shown
persist
viraemia
end
therapi
associ
higher
risk
diseas
relaps
altern
therapi
food
drug
administrationapprov
use
solid
organ
transplant
recipi
includ
foscarnet
cidofovir
leflunomid
reserv
treatment
antivir
resist
foscarnet
activ
ganciclovirresist
strain
cmv
neurotox
renal
toxic
sever
magnesium
wast
cidofovir
use
renal
transplant
recipi
howev
often
nephrotox
foscarnet
cidofovir
may
exhibit
synergist
nephrotox
calcineurin
inhibitor
one
biggest
challeng
regard
treatment
cmv
emerg
antivir
resist
although
commonli
note
lung
pancrea
transplant
recipi
cmv
resist
ganciclovir
observ
renal
transplant
recipi
ganciclovir
resist
suspect
patient
persist
unchang
viremia
andor
symptom
week
therapi
case
genotyp
assay
detect
mutat
associ
antivir
resist
perform
treatment
resist
isol
may
includ
use
foscarnet
without
ganciclovir
cidofovir
small
case
studi
demonstr
efficaci
leflunomid
treat
cmv
diseas
renal
transplant
patient
prospect
studi
patient
treat
leflunomid
cmv
demonstr
viral
clearanc
heal
infect
organ
patient
potenti
therapeut
agent
multidrugresist
cmv
includ
immunoglobulin
leflunomid
artesun
although
data
support
use
remain
anecdot
henc
need
identifi
novel
agent
strategi
manag
cmv
infect
diseas
human
herpesviru
simplex
viru
hsv
belong
subfamili
alphaherpesvirina
genu
simplexviru
speci
human
herpesviru
seropreval
adult
popul
incid
hsv
renal
transplant
recipi
estim
approxim
hsv
commonli
caus
reactiv
infect
may
caus
primari
infect
transmit
persontoperson
contact
via
allograft
follow
primari
infect
viru
remain
latent
sensori
nerv
ganglia
absenc
prophylaxi
hsv
may
seen
earli
first
posttranspl
month
reactiv
primari
hsv
infect
result
oral
genit
mucocutan
lesion
occasion
caus
pneumon
tracheobronch
esophag
hepat
dissemin
infect
diseas
may
sever
invas
prolong
transplant
recipi
hsv
esophag
may
present
superfici
punchedout
lesion
may
superinfect
candida
hsv
common
form
enceph
transplant
recipi
hsv
pcr
cultur
cerebrospin
fluid
assist
diagnosi
diffus
interstiti
pneumon
may
complic
dissemin
diseas
multiviscer
involv
hsv
infect
often
fatal
diagnosi
may
made
aid
direct
fluoresc
antibodi
hsv
vesicular
lesion
pcr
cerebrospin
fluid
viscer
tissu
sampl
due
high
seropreval
adult
popul
serolog
rare
help
set
activ
infect
treatment
hsv
infect
acyclovir
shown
effect
mucocutan
hsv
infect
solidorgan
transplant
recipi
treat
oral
acyclovir
dissemin
deep
hsv
infect
alway
treat
intraven
acyclovir
dose
adjust
patient
renal
failur
although
toxic
acyclovir
ganciclovir
foscarnet
also
effect
hsv
concern
respect
chronic
acyclovir
use
develop
resist
mutant
hsv
acyclovir
resist
may
aris
mutat
gene
thymidin
kinas
dna
polymeras
acyclovir
resist
rare
report
strain
foscarnet
cidofovir
topic
trifluridin
may
consid
treatment
resist
viru
although
care
monitor
renal
function
requir
human
herpesviru
zoster
vzv
belong
subfamili
alphaherpesvirina
genu
varicelloviru
speci
human
herpesviru
vzv
caus
two
distinct
clinic
diseas
follow
transplant
nineti
percent
adult
solidorgan
transplant
recipi
vzv
seroposit
pretransplant
thu
vzv
reactiv
group
caus
herp
zoster
remain
vzv
seroneg
thu
risk
primari
infect
incid
vzv
renal
transplant
recipi
lower
hsv
approxim
vzv
caus
spectrum
diseas
solid
organ
transplant
recipi
rang
local
dermatom
zoster
involv
adjoin
dermatom
multidermatom
dissemin
zoster
without
viscer
involv
cohort
adult
solid
organ
transplant
renal
transplant
recipi
renal
transplant
recipi
herp
zoster
median
time
onset
month
main
complic
vzv
infect
immunosuppress
popul
dissemin
intravascular
coagul
dic
hepat
almost
half
pneumon
patient
infect
allograft
cn
well
pancreat
also
describ
concomit
bacteri
cmv
infect
report
unilater
vesicular
lesion
dermatom
pattern
usual
suffici
characterist
herp
zoster
enabl
clinic
diagnosi
howev
cultur
vzv
suscept
cell
cultur
line
demonstr
multinucl
giant
cell
tzanck
smear
andor
direct
immunofluoresc
recommend
confirm
techniqu
also
use
diagnosi
case
primari
infect
pretranspl
screen
previou
vzv
infect
perform
patient
vaccin
live
attenu
varicella
vaccin
transplant
whenev
possibl
avoid
primari
vzv
infect
transplant
often
sever
diseas
high
mortal
rate
howev
due
fact
vzv
vaccin
live
vaccin
vaccin
scientif
world
journal
given
transplant
expect
within
four
six
week
prevent
activ
viral
shed
time
transplant
vzv
transplant
patient
expos
someon
infect
varicella
receiv
varicella
immun
globulin
within
hour
exposur
avail
vzig
avail
patient
present
greater
hour
follow
exposur
acyclovir
may
consid
postexposur
prophylaxi
posttranspl
prophylaxi
reactiv
vzv
also
hsv
recommend
prevent
sever
recurr
consist
ganciclovir
patient
need
cmv
prophylaxi
patient
requir
cmv
prophylaxi
receiv
valacyclovir
acyclovir
approxim
one
three
month
posttranspl
transplant
author
defer
vaccin
live
vaccin
kill
vaccin
appear
benefici
vzimmunoglobulin
recommend
immunocompromis
individu
exposur
varicella
zoster
protect
incomplet
epsteinbarr
virushuman
herpesviru
ebv
belong
subfamili
gammaherpesvirina
genu
lymphocryptoviru
speci
human
herpesviru
infect
b
lymphocyt
well
malign
cell
sever
lineag
includ
lymphocyt
epitheli
cell
smooth
muscl
cell
ebv
associ
wide
rang
malign
includ
posttranspl
lymphoprolif
disord
ptld
hodgkin
nonhodgkin
lymphoma
nasopharyng
carcinoma
gastric
carcinoma
leiomyosarcoma
nearli
everi
human
infect
adulthood
infect
earli
childhood
usual
asymptomat
delay
primari
infect
typic
manifest
symptom
infecti
mononucleosi
infect
occur
viral
genom
maintain
life
small
fraction
b
lymphocyt
set
allogen
transplant
iatrogen
immunosuppress
use
prevent
graft
reject
unintend
consequ
failur
suppress
activ
ebv
infect
accompani
heighten
risk
develop
ptld
ptld
potenti
lifethreaten
neoplasm
exhibit
spectrum
histopatholog
rang
reactiveappear
polyclon
lymphoid
infiltr
sheet
undifferenti
cell
morpholog
indistinguish
malign
lymphoma
plasma
cell
myeloma
major
symptomat
infect
renal
transplant
recipi
primari
infect
like
relat
reactiv
donor
viru
sinc
nineti
percent
adult
antibodi
ebv
age
symptomat
infect
commonli
seen
pediatr
popul
renal
transplant
lowest
risk
acquir
ptld
comparison
transplant
popul
approxim
ptld
commonli
occur
first
year
transplant
symptom
often
quit
nonspecif
exampl
fever
malais
anorexia
patient
asymptomat
ptld
frequent
present
rapidli
enlarg
mass
graft
organ
lymph
node
fill
marrow
space
extranod
site
upper
airway
intestin
nearli
transplant
recipi
infect
eventu
becom
infect
ebv
yet
fraction
develop
ptld
risk
factor
ptld
follow
ebv
seroneg
time
transplant
activ
primari
ebv
infect
time
transplant
underli
diseas
lead
transplant
prior
splenectomi
second
transplant
patient
age
children
older
adult
coinfect
cytomegaloviru
virus
acut
chronic
graftversushost
diseas
immunosuppress
drug
regimen
intens
cytokin
polymorph
hla
type
extent
hla
mismatch
presenc
multipl
risk
factor
activ
primari
ebv
infect
contraind
transplant
type
immunosuppress
alter
risk
develop
ptld
higher
incid
rate
observ
patient
receiv
cytolyt
therapi
includ
antithymocyt
globulin
fludarabin
azathioprin
agent
caus
profound
tcell
suppress
mutagen
also
implic
ptld
pathogenesi
ptld
divid
four
major
histopatholog
subtyp
correspond
clinic
biolog
featur
describ
world
health
organ
subclassif
scheme
includ
earli
lesion
polymorph
ptld
monomorph
ptld
classic
hodgkin
lymphoma
type
ptld
although
lesion
may
bear
microscop
resembl
diseas
aris
sporad
otherwis
healthi
individu
eg
infecti
mononucleosi
diffus
larg
bcell
lymphoma
myeloma
hodgkin
lymphoma
agerel
bcell
lymphoprolif
disord
occurr
set
transplant
warrant
diagnosi
ptld
given
natur
histori
recommend
therapi
ptld
differ
lesion
similar
histolog
featur
nonimmunocompromis
host
term
natur
histori
ptld
almost
alway
progress
quit
rapidli
fatal
conclus
unless
promptli
recogn
treat
abil
reduc
elimin
immunosuppress
drug
help
strategi
restor
natur
antivir
antineoplast
immun
biopsi
necessari
confirm
diagnosi
ptld
rule
neoplast
infecti
lesion
histochem
stain
help
narrow
differenti
diagnosi
immunohistochemistri
somewhat
less
reliabl
sinc
viral
protein
may
express
focal
inconsist
ptld
case
ebv
infect
ebv
load
test
commonli
use
assist
diagnosi
monitor
transplant
recipi
despit
pauciti
clinic
trial
demonstr
util
ebv
dna
measur
set
indic
ebv
load
test
immunosuppress
transplant
recipi
typic
includ
lymphadenopathi
mass
lesion
organ
dysfunct
fever
malais
sign
symptom
suggest
ptld
addit
routin
monitor
ebv
load
highrisk
patient
help
identifi
ptld
sign
symptom
appear
ebv
load
laboratori
establish
threshold
ptld
convey
clinician
immedi
may
trigger
search
put
site
diseas
follow
biopsi
reason
establish
histopatholog
diagnosi
even
absenc
biopsydiagnos
ptld
preemptiv
intervent
may
scientif
world
journal
use
resolv
laboratorydetect
diseas
preemptiv
therapi
may
includ
reduc
immunosuppress
infus
antibodi
donor
cell
patient
high
risk
ptld
eg
intens
immunosuppress
seroneg
time
transplant
tend
monitor
frequent
eg
weekli
first
month
transplant
monthli
preemptiv
therapi
may
consid
optim
design
trial
measur
ebv
load
monthli
first
year
patient
continu
frequent
monitor
beyond
first
year
histori
high
ebv
load
drug
regimen
particularli
immunosuppress
aftermath
discontinu
antivir
prophylaxi
european
best
practic
guidelin
renal
transplant
recommend
use
ebv
load
gaug
intervent
practic
guidelin
kidney
diseas
improv
global
outcom
transplant
work
group
recommend
highrisk
renal
transplant
patient
test
ebv
nucleic
acid
within
first
week
transplant
least
monthli
month
everi
month
rest
first
year
addit
ebv
test
recommend
treatment
acut
reject
clinic
manag
ptld
typic
involv
reduc
iatrogen
immunosuppress
natur
immun
ebv
neoplast
clone
restor
complementari
intervent
includ
infus
donor
lymphocyt
infus
ebvspecif
cytotox
cell
grown
ex
vivo
expos
hlamatch
cell
ebv
antigen
infus
monoclon
antibodi
eg
rituximab
initi
intervent
insuffici
tradit
cancer
treatment
radiat
multidrug
chemotherapi
use
antivir
therapi
acyclovir
ganciclovir
remain
controversi
agent
activ
latent
form
ebv
found
ptld
outcom
ptld
renal
transplant
recipi
vari
depend
site
involv
patient
isol
allograft
involv
fiveyear
surviv
approxim
compar
patient
ptld
extend
beyond
transplant
kidney
whose
fiveyear
surviv
vari
percent
human
herpesviru
human
herpesviru
hhv
hhv
belong
subfamili
betaherpesvirina
genu
roseoloviru
speci
human
herpesviru
human
herpesviru
virus
ubiquit
high
seropreval
adult
primari
infect
virus
establish
latent
persist
infect
remain
lifetim
host
virus
lymphotrop
hhv
particular
use
molecul
receptor
may
also
infect
cell
type
monocyt
epitheli
endotheli
cell
isol
classifi
two
variant
term
hhv
hhv
basi
distinct
genet
antigen
biolog
characterist
specif
pathogen
variant
remain
poorli
understood
infect
renal
transplant
recipi
due
hhv
use
molecul
receptor
strictli
lymphotropicth
stimulu
reactiv
betaherpesvirus
renal
transplant
recipi
immunosuppress
regimen
addit
virus
possess
immunomodul
properti
includ
abil
alter
express
immun
activ
molecul
modul
express
sever
cytokin
chemokin
induc
apoptosi
lymphocyt
may
contribut
immunosuppress
product
infect
cell
result
cytopath
effect
cell
destruct
ubiquit
natur
hhv
hhv
creat
condit
develop
concurr
infect
interact
virus
kinet
activ
virus
posttransplant
period
suggest
hhv
may
act
cofactor
hhv
cmv
reactiv
hhv
hhv
may
act
cofactor
pathogenesi
cmv
diseas
acut
reject
hhv
associ
fever
rash
enceph
hepat
myelosuppress
interstiti
pneumon
diagnos
hhv
hhv
infect
made
qualit
quantit
molecular
assay
tissu
immunohistochemistri
andor
peripher
blood
mononuclear
cell
cultur
treatment
similar
cmv
involv
reduct
immunosuppress
ganciclovir
cidofovir
foscarnet
also
util
human
herpesviru
hhv
belong
subfamili
gammaherpesvirina
genu
rhadinoviru
speci
human
herpesviru
hhv
associ
kaposi
sarcoma
primari
effus
lymphoma
multicentr
castleman
diseas
lymphoprolif
disord
infect
renal
transplant
popul
thought
commonli
happen
reactiv
latent
viru
although
primari
infect
transplant
occur
acquir
allograft
transplantationassoci
kaposi
sarcoma
occur
renal
transplant
recipi
vari
ethnic
group
immunosuppress
regimen
tumor
solidorgan
transplant
kaposi
sarcoma
occur
shortest
interv
transplant
hhv
thought
lead
kaposi
sarcoma
upregul
vascular
endotheli
growth
factor
vegf
receptor
endotheli
cell
therapi
kaposi
sarcoma
includ
reduct
immunosuppress
cytotox
chemotherapi
sirolimu
rapamycin
immunosuppress
drug
use
kidneytranspl
recipi
probabl
antineoplast
effect
immunosuppress
antineoplast
effect
sirolimu
may
due
common
mechan
thought
sirolimu
inhibit
product
vegf
also
dampen
effect
endotheli
cell
suggest
sirolimu
inhibit
progress
kaposi
sarcoma
kidneytranspl
recipi
exert
antireject
effect
organ
allograft
scientif
world
journal
bk
polyomaviru
bkv
jc
polyomaviru
jcv
simian
viru
belong
famili
polyomavirida
genu
polyomaviru
last
year
improv
immunosuppress
drug
decreas
rate
acut
reject
kidney
transplant
also
led
emerg
polyomavirusassoci
nephropathi
pvan
occur
patient
kidney
transplant
caus
bk
viru
case
less
case
attribut
jc
viru
initi
lack
recognit
late
diagnosi
pvan
result
rapid
loss
graft
function
patient
serolog
evid
past
bkv
exposur
seen
reach
adolesc
adult
around
world
seem
chang
sinc
first
discoveri
bkv
similar
earlier
studi
hirsch
et
al
found
seroposit
prospect
studi
patient
kidney
transplant
accordingli
mismatch
bkv
serostatu
donor
graft
recipi
significantli
less
frequent
cytomegaloviru
mismatch
absenc
chang
explain
emerg
pvan
last
decad
howev
higher
bkv
antibodi
titer
kidney
donor
lower
titer
recipi
identifi
risk
factor
bkv
replic
viremia
posttransplant
recent
increas
bk
infect
attribut
part
use
potent
immunosuppress
regimen
howev
specif
immunosuppress
medic
combin
demonstr
increas
risk
nephropathi
caucasian
race
cadaver
renal
transplant
older
age
presenc
diabet
combin
kidney
pancrea
transplant
shown
associ
bk
viru
nephropathi
primari
infect
bkv
jcv
typic
subclin
link
mild
respiratori
ill
follow
viral
dissemin
site
lifelong
persist
infect
major
site
persist
bkv
jcv
cell
kidney
urinari
tract
bkv
dna
found
normal
kidney
tissu
distribut
pattern
small
foci
throughout
cortex
medulla
uret
jcv
dna
detect
approxim
normal
kidney
sampl
reactiv
latent
viru
report
old
age
pregnanc
diabet
mellitu
immunosuppress
associ
congenit
immunodefici
organ
transplant
hiv
infect
strike
featur
bk
infect
kidney
transplant
recipi
lack
fever
malais
myalgia
leukopenia
anemia
thrombocytopenia
symptom
sign
typic
viral
infect
despit
viral
load
exceed
billion
copiesml
urin
copiesml
blood
bkv
nephropathi
present
renal
dysfunct
without
clinic
sign
symptom
although
jc
viru
rare
implic
caus
nephropathi
either
alon
combin
bk
commonli
seen
caus
progress
multifoc
leukoencephalopathi
demyelin
process
involv
cerebr
white
matter
present
symptom
includ
progress
neurolog
impair
progress
dementia
laboratori
monitor
strategi
bkv
still
evolv
quantit
nucleic
acidbas
viral
load
assay
urin
blood
becom
wide
use
bkv
screen
detect
viru
blood
predict
bkvn
viruria
alon
medic
center
prefer
urin
cytolog
primari
screen
techniqu
urinari
decoy
cell
excel
sensit
detect
overt
bkvn
polymeras
chain
reaction
pcr
four
time
sensit
urin
cytolog
monitor
asymptomat
viruria
addit
pcr
provid
object
estim
true
viral
load
distinguish
bk
viruria
jc
viruria
jcv
excret
urin
usual
insignific
although
rare
case
jcv
associ
interstiti
nephriti
record
decoy
cell
stabl
wherea
dna
pcr
may
use
monitor
patient
distanc
transplant
center
rel
cost
pcr
versu
cytolog
centerdepend
variabl
laboratori
screen
bkv
certainli
done
unexplain
rise
serum
creatinin
cost
screen
found
substanti
offset
save
relat
reduct
immunosuppress
follow
diagnosi
bkvn
antivir
agent
administ
definit
diagnosi
bkvn
requir
biopsi
demonstr
bkv
inclus
tubular
epitheli
bowman
capsular
epitheli
cell
viral
infect
accompani
vari
degre
inflammatori
cell
infiltr
tubular
atrophi
fibrosi
cytopath
effect
seen
light
microscopi
typic
pathognomon
bkvn
confirmatori
immunohistochemistri
situ
hybrid
studi
usual
perform
use
antibodi
specif
bkv
protein
probe
complementari
viral
dna
electron
microscopi
use
demonstr
unenvelop
viral
particl
approxim
nm
diamet
sinc
bkvn
focal
distribut
ideal
two
biopsi
core
examin
avail
medullari
parenchyma
increas
diagnost
sensit
neg
biopsi
result
rule
bkvn
certainti
diagnosi
presumpt
bkvn
made
renal
allograft
dysfunct
associ
bk
viremia
definit
diagnosi
reject
concurr
viral
nephropathi
made
endarter
fibrinoid
arteri
necrosi
glomerul
accumul
complement
degrad
product
along
peritubular
capillari
bk
jc
shed
report
coexist
patient
decoy
cell
longterm
prognosi
find
similar
patient
pure
bk
shed
publish
case
pvan
attribut
jc
viru
cohort
patient
screen
decoy
cell
found
jc
shed
urin
patient
older
show
decoy
cell
appear
later
compar
patient
pure
bk
shed
among
six
patient
jcvassoci
nephropathi
document
posit
cytolog
posit
plasma
quantit
pcr
posit
stain
decreas
immunosuppress
mani
patient
continu
shed
jcv
stabl
serum
creatinin
indic
biopsi
presenc
decoy
cell
urin
patient
graft
dysfunct
loss
progress
multifoc
leukoencephalopathi
complic
jcv
infect
typic
found
patient
hiv
infect
rare
report
renal
transplant
recipi
reductionadjust
immunosuppress
remain
cornerston
treatment
prevent
pvan
reconstitut
immun
system
control
infect
take
week
imper
start
treatment
earli
possibl
one
risk
encount
reduct
immunosuppress
develop
acut
reject
preliminari
result
wali
et
al
reflect
protocol
use
univers
maryland
consist
intens
screen
subsequ
stepwis
decreas
immunosuppress
protocol
result
clearanc
vm
graft
loss
signific
reject
diagnos
specif
immunosuppress
reduct
follow
step
decreas
dose
mmf
immedi
diagnosi
step
decreas
target
trough
level
tacrolimu
month
decoy
cell
persist
step
elimin
mmf
month
decoy
cell
persist
mainten
dual
therapi
consist
modifi
dose
tacrolimu
mainten
dose
prednison
exceed
mg
per
week
addit
decreas
immunosuppress
sever
center
report
use
sever
antipolyomavir
agent
antibkv
activ
vitro
includ
cidofovir
leflunomid
quinolon
intraven
immunoglobulin
none
agent
approv
food
drug
administr
pvan
treatment
howev
use
empir
mani
case
advanc
stage
diseas
graft
dysfunct
persist
worsen
efficaci
antivir
agent
difficult
determin
use
combin
reduct
immunosuppress
even
certain
case
combin
addit
prospect
random
control
trial
conduct
summari
examin
avail
literatur
demonstr
none
ancillari
treatment
describ
conclus
proven
efficaci
studi
neither
random
doubleblind
histolog
grade
pvan
often
miss
addit
mani
case
renal
dysfunct
present
time
diagnosi
multicent
prospect
studi
need
clarifi
import
issu
stratifi
histolog
grade
renal
function
viral
load
diagnosi
importantli
evalu
differ
strategi
assess
independ
earli
diagnosi
close
monitor
renal
function
andseri
determin
vm
continu
repres
efficaci
tool
control
pvan
systemat
reduct
immunosuppress
associ
clear
evid
increas
chronic
reject
longer
time
followup
stringent
studi
necessari
determin
longterm
impact
intervent
pvan
longterm
graft
outcom
hepat
b
viru
hbv
belong
famili
hepadnavirida
genu
orthohepadnaviru
speci
hepat
b
viru
patient
chronic
kidney
diseas
undergo
renal
transplant
despit
improv
outcom
liver
diseas
persist
import
caus
morbid
mortal
preval
hepat
b
viru
infect
among
patient
renal
replac
therapi
decreas
implement
prevent
strategi
dialysi
popul
current
estim
preval
hepat
diseas
popul
rang
percent
approxim
percent
patient
histori
hepat
b
transplant
reactiv
posttranspl
import
factor
influenc
hbsag
seroposit
statu
recipi
acquisit
hbv
infect
renal
transplant
via
infect
graft
surgeri
era
increas
emigr
peopl
high
endem
area
industri
countri
hbv
infect
remain
persist
concern
public
health
author
impact
hbsag
seroposit
statu
patient
surviv
renal
transplant
controversi
initi
report
mostli
focus
surviv
rate
gener
fail
show
differ
hbsagposit
neg
renal
transplant
patient
contrast
studi
appropri
size
longer
followup
found
unfavor
effect
hbsag
mathurin
colleagu
report
patient
surviv
significantli
higher
noninfect
hbsagposit
recipi
recipi
antihepat
c
viru
hcv
posit
multivari
analysi
demonstr
hbsag
independ
factor
associ
inferior
patient
surviv
year
p
fabrizi
colleagu
subsequ
metaanalysi
show
hbsag
seroposit
statu
independ
risk
factor
death
recent
studi
mato
colleagu
attempt
identifi
factor
increas
liver
fibrosi
format
renal
transplant
patient
hbv
infect
follow
patient
mean
time
year
posttranspl
liver
biopsi
postren
transplant
advanc
fibrosi
compar
mild
fibrosi
logist
regress
analysi
appli
variabl
age
sex
estim
time
sinc
infect
histori
renal
transplant
donor
type
alt
index
hbeag
antihcv
quantit
hbv
dna
postrt
time
hbvhcv
coinfect
sixtysix
percent
patient
cyclosporinebas
regimen
independ
factor
associ
advanc
fibrosi
increas
length
time
transplant
immunosuppress
postren
transplant
may
augment
hbv
replic
varieti
mechan
includ
diminish
activ
cytotox
lymphocyt
azathioprin
may
stimul
intracellular
hbv
synthesi
furthermor
calcineurin
inhibitor
cni
may
direct
effect
hbv
replic
reactiv
hbv
infect
even
hb
agseroneg
individu
whose
serolog
profil
indic
remot
resolv
hbv
infect
recogn
transplant
reappear
scientif
world
journal
hbsag
serum
newli
recogn
hbv
infect
renal
transplant
reflect
de
novo
infect
reactiv
prior
resolv
infect
investig
observ
renal
transplant
recipi
transplant
increas
replic
reappear
increas
serum
hbv
dna
level
hbeag
well
reappear
serum
hbsag
follow
appar
clearanc
prior
hbv
infect
reactiv
may
caus
necroinflammatori
liver
injuri
biochem
dysfunct
recent
case
reactiv
hbv
rt
report
fulmin
hepat
failur
due
hbv
reactiv
alreadi
note
renal
transplant
propos
theori
viral
reactiv
rt
follow
first
hypothesi
includ
occult
hbv
infect
rt
candid
transplant
viral
replic
hbv
influenc
immunosuppress
anoth
theori
loss
protect
immun
infect
mutat
strain
natur
occur
mutat
prec
region
core
promot
region
found
patient
longstand
chronic
hbv
infect
renal
transplant
recipi
increas
risk
develop
varieti
cancer
hepatocellular
carcinoma
usual
associ
viral
hepat
hbv
hcv
report
postren
transplant
recipi
without
overt
evid
viral
hepat
cirrhosi
metabol
liver
diseas
effect
safe
vaccin
contain
hbsag
initi
plasma
deriv
recent
manufactur
recombin
dna
technolog
avail
sinc
earli
vaccin
hbv
recommend
suscept
patient
dialysi
ie
antihepat
b
surfac
titer
iuml
patient
mainten
dialysi
suboptim
respons
hbv
vaccin
compar
gener
popul
respons
sever
approach
tri
enhanc
respons
rate
hbv
vaccin
patient
includ
administr
doubl
multipl
dose
hbv
vaccin
intraderm
administr
vaccin
vaccin
simultan
use
adjuv
granulocyt
macrophagestimul
factor
thymopentin
erythropoietin
zinc
supplement
etc
current
recommend
hbv
vaccin
suscept
dialysi
patient
administr
doubl
dose
dose
intramuscular
rout
month
evalu
donor
includ
test
suspect
hbv
infect
includ
hbsag
hbsab
antihbc
risk
hbv
transmiss
renal
transplant
recipi
function
serolog
statu
donor
recipi
donor
hbsabposit
serolog
due
vaccin
transmit
hbv
infect
donor
isol
antihbcposit
serolog
serolog
test
done
differenti
acut
infect
remot
exposur
igm
anticor
detect
patient
may
recent
acut
hbv
infect
use
hbv
naiv
recipi
without
antivir
prophylaxi
although
liver
harvest
isol
antihbc
posit
donor
consider
risk
hbv
transmiss
recipi
liver
graft
kidney
donor
carri
low
risk
transmiss
kidney
hbsagposit
donor
higher
risk
transmit
hbv
infect
recipi
risk
transmiss
greater
donor
statu
hbsag
posit
along
hbeag
posit
hbsabposit
recipi
requir
prophylaxi
hand
organ
hbsagposit
donor
use
hbcabpositivehbsabposit
recipi
requir
lamivudin
prophylaxi
year
licens
drug
avail
treatment
chronic
hbv
interferon
lamivudin
adefovir
entecavir
telbivudin
tenofovir
date
interferon
promis
manag
hbv
renal
transplant
recipi
studi
regard
use
telbivudin
tenofovir
renal
transplant
howev
manag
hbv
renal
transplant
given
encourag
result
lamivudin
adefovir
entecavir
role
liver
biopsi
evalu
rt
candid
hbsag
import
difficult
clinic
ground
alon
estim
sever
liver
diseas
ckd
popul
patient
establish
cirrhosi
liver
biopsi
risk
hepat
decompens
isol
rt
kidney
transplant
alon
contraind
patient
normal
renal
function
antivir
therapi
report
lead
regress
advanc
histolog
lesion
similar
hepat
b
hepat
c
complex
problem
renal
transplant
recipi
hepat
c
viru
belong
famili
flavivirida
genu
hepaciviru
speci
hepat
c
viru
incid
rate
chronic
diseas
popul
decreas
averag
percent
per
year
recognit
hepat
c
patient
chronic
renal
failur
may
confound
limit
sensit
serolog
diagnosi
popul
hepat
c
seroneg
transplant
candid
abnorm
transaminas
andor
risk
factor
hepat
c
undergo
nucleic
acid
test
increas
risk
progress
liver
diseas
follow
transplant
patient
hepat
c
undergo
liver
biopsi
exclud
advanc
liver
diseas
case
may
necessit
combin
liverkidney
transplant
hepatitiscposit
patient
usual
mark
rise
viral
load
initi
immunosuppress
immedi
transplant
chronic
immunosuppress
use
transplant
recipi
also
lead
higher
circul
level
viru
intrahepat
viru
due
decreas
tcell
respons
region
hepat
c
viru
consequ
patient
hepat
c
increas
risk
progress
liver
diseas
develop
cirrhosi
follow
transplant
larg
demand
organ
consider
given
use
hepatitiscposit
donor
transplant
recipi
may
acquir
hepat
c
transplant
may
lead
sever
hepat
although
recipi
hcv
posit
kidney
diminish
patient
graft
surviv
compar
recipi
hcvneg
kidney
surviv
may
improv
compar
surviv
dialysi
problem
antihcv
therapi
interferon
ifn
associ
increas
risk
allograft
reject
function
graft
also
alreadi
fail
graft
therefor
may
explain
major
hesit
use
ifna
renal
transplant
recipi
increas
reject
possibl
cytokin
gene
express
increas
cell
surfac
express
hla
antigen
enhanc
function
natur
killer
cell
cytotox
cell
monocyt
immunestimul
effect
result
enhanc
allograft
rejectionwhich
may
irreversibleeven
patient
stabl
graft
indic
patient
fibros
cholestat
hepat
condit
benefit
treatment
outweigh
risk
allograft
loss
extrem
limit
data
evalu
efficaci
complic
ifna
therapi
treatment
possibl
hcvrelat
cryoglobulinemia
de
novo
recurr
glomerular
diseas
renal
transplant
recipi
pageaux
et
al
show
treatment
hcv
ifn
transplant
might
riski
initi
shown
posttranspl
monotherapi
ribavirin
andor
amantadin
appar
impact
hcv
viremia
liver
histolog
best
strategi
treat
hcv
infect
patient
dialysi
transplant
exclud
cirrhosi
liver
biopsi
present
patient
consid
combin
kidneyliv
transplant
strategi
could
prevent
liver
diseas
progress
even
hcvrelat
morbid
glomerulonephr
posttranspl
diabet
mellitu
human
immunodefici
viru
hiv
belong
famili
retrovirida
genu
lentiviru
speci
human
immunodefici
viru
hiv
infect
major
global
health
problem
almost
three
decad
introduct
highli
activ
antiretrovir
therapi
haart
advent
effect
prophylaxi
manag
opportunist
infect
aid
mortal
decreas
markedli
develop
countri
fatal
infect
treat
chronic
condit
result
rate
morbid
mortal
medic
condit
lead
endstag
liver
kidney
heart
diseas
steadili
increas
individu
hiv
renal
diseas
directli
relat
hiv
infect
includ
hivassoci
nephropathi
hivan
immun
complex
diseas
thrombot
microangiopathi
although
widespread
use
haart
decreas
incid
hivrel
renal
diseas
overal
preval
renal
diseas
continu
increas
among
patient
hiv
aggress
hivrel
renal
diseas
hivan
occur
approxim
patient
hiv
patient
progress
endstag
renal
diseas
esrd
within
week
month
recent
studi
confirm
outcom
renal
transplant
adequ
select
hivinfect
patient
receiv
kidney
hivneg
donor
similar
hivneg
rt
recipi
main
challeng
clinic
manag
hivinfect
rt
recipi
pharmacolog
interact
immunosuppress
agent
class
antiretrovir
drug
higher
rate
acut
reject
comparison
hivneg
rt
recipi
current
organ
transplant
hivinfect
donor
absolut
contraind
western
countri
potenti
util
consider
recent
muller
et
al
report
outcom
four
hivinfect
rt
recipi
receiv
graft
two
hivinfect
donor
south
africa
first
clinic
experi
publish
involv
type
transplant
month
followup
recipi
function
renal
allograft
good
renal
function
hiv
infect
control
differ
antiretrovir
regimen
south
africa
countri
high
hiv
preval
gener
popul
hiv
infect
absolut
exclus
criterion
access
dialysi
rt
muller
et
al
suggest
use
hivinfect
donor
would
increas
donor
pool
provid
renal
allograft
hivinfect
patient
otherwis
sentenc
death
consequ
endstag
renal
diseas
deceas
hivinfect
patient
repres
potenti
approxim
donor
per
year
hivinfect
transplant
candid
current
era
hiv
manag
legal
ban
use
organ
seem
unwarr
like
harm
hivinfect
patient
receiv
renal
transplant
may
higher
risk
acut
reject
optim
manag
immunosuppress
hivinfect
individu
remain
unknown
treatment
reject
cytolyt
agent
thymoglobulin
may
result
prolong
depress
count
signific
infectionrel
morbid
risk
antilymphocyt
therapi
balanc
risk
reject
hivinfect
recipi
variou
virus
caus
respiratori
diseas
renal
transplant
popul
includ
adenoviru
respiratori
syncyti
viru
influenza
parainfluenza
human
metapneumoviru
rhinoviru
coronaviru
virus
lead
upper
respiratori
tract
diseas
well
bronchiti
pneumon
pneumonia
adenoviru
caus
multitud
complic
includ
gastroenter
cystiti
necrot
hepat
addit
respiratori
ill
immunocompromis
patient
adenoviru
infect
tend
prolong
sever
sometim
fatal
may
occur
due
endogen
reactiv
primari
infect
coinfect
one
adenoviru
serotyp
per
clinic
event
frequent
immunocompromis
patient
immunocompet
patient
clinic
manifest
immunocompromis
patient
includ
pneumonia
hepat
hemorrhag
cystiti
coliti
pancreat
meningoenceph
dissemin
diseas
depend
underli
diseas
affect
organ
system
patient
age
viru
serotyp
renal
transplant
recipi
adenoviru
also
caus
nephriti
present
fever
renal
dysfunct
liver
function
test
abnorm
infect
respiratori
virus
may
also
associ
reject
sever
diseas
greatest
recent
transplant
immunosuppress
clinician
pathologist
vigil
awar
av
nephriti
renal
allograft
diagnosi
difficult
laboratori
perform
immunohistochemistri
av
multipl
diagnost
modal
includ
immunohistochemistri
biopsi
materi
serolog
viral
cultur
viral
gene
pcr
may
requir
make
diagnosi
patholog
clue
diagnosi
av
infect
includ
gross
haematuria
often
sever
haemorrhag
cystiti
fever
without
pneumon
renal
biopsi
presenc
tubulointerstiti
necrosi
haemorrhag
atyp
smudg
epitheli
cell
help
recogn
lesion
although
av
infect
occur
within
week
month
transplant
due
activ
latent
infect
av
infect
also
uncommonli
occur
year
later
may
due
de
novo
av
infect
prevent
involv
avoid
individu
sign
symptom
infect
hand
hygien
use
droplet
precaut
suspect
infect
influenza
vaccin
administ
transplant
everi
year
transplant
although
administr
given
earli
posttranspl
period
especi
reduc
vaccin
respons
vaccin
may
insuffici
protect
patient
transplant
influenza
vaccin
also
administ
patient
famili
member
health
care
provid
decreas
possibl
risk
transmiss
intranas
influenza
vaccin
use
util
live
viru
morelon
et
al
suggest
intraderm
influenza
vaccin
may
offer
enhanc
immunogen
protect
person
respond
well
convent
trival
inactiv
influenza
vaccin
studi
conduct
immunocompromis
popul
valid
trend
higher
efficaci
id
versu
convent
rout
immun
influenza
treatment
respiratori
viral
infect
involv
support
care
case
use
antivir
medic
influenza
treat
oseltamivir
zanamavir
treat
influenza
b
amantadin
recommend
treat
influenza
increas
rate
resist
seen
influenza
ribavirin
approv
treat
lower
respiratori
infect
respiratori
syncyti
viru
howev
actual
clinic
efficaci
proven
sever
adenoviru
infect
usual
treat
reduct
immunosuppress
anecdot
report
suggest
cidofovir
may
activ
adenoviru
use
must
balanc
associ
risk
nephrotox
west
nile
viru
wnv
belong
famili
flavivirida
genu
flaviviru
speci
west
nile
viru
sinc
isol
uganda
wnv
respons
thousand
case
morbid
mortal
bird
hors
human
histor
epidem
local
europ
africa
middl
east
part
asia
primarili
caus
mild
febril
ill
human
howev
late
viru
becam
virul
expand
geograph
rang
north
america
human
clinic
present
rang
asymptomat
approxim
infect
encephalitisparalysi
death
less
infect
wnv
recent
transmit
one
donor
like
relat
blood
transfus
multipl
recipi
transplant
recipi
higher
risk
gener
popul
meningoenceph
exposur
wnv
endem
region
donor
test
wnv
viru
donor
increas
morbid
mortal
recipi
acquir
west
nile
later
transplant
cours
variabl
outcom
prevent
infect
season
screen
consid
donor
transplant
serolog
andor
nucleic
acid
test
treatment
west
nile
transplant
recipi
standard
includ
reduct
immunosuppress
along
support
care
whether
role
hyperimmun
globulin
transplant
recipi
current
unknown
viral
infect
renal
transplant
patient
continu
signific
impact
patient
outcom
although
prevent
measur
improv
impact
newer
immunosuppress
strategi
continu
promot
develop
sever
viral
infect
presenc
new
emerg
viral
infect
may
transmit
transplant
west
nile
viru
like
present
mani
futur
challeng
physician
treat
transplant
recipi
